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Summary
Background: Gaucher disease (GD) is an autosomal recessive disorder produced by mutations in the glucocerebrosidase
gene (GBA), causing storage of glucosylceramide in reticuloendothelial cells in multiple organs. Traditionally, the prediction
of the phenotype based on the genotype has been reported to be limited.
Subjects and Methods: We investigated the correlation between the enzymatic residual activity (ERA) and the phenotype at
diagnosis of the disease in 45 GD Spanish patients (44 with type I and 1 with type III GD). The genotype involved two of the
following previously expressed proteins: c.517A>C (T134P), 1%; c.721G>A (G202R), 17%; c.1090G>T (G325W), 13.9%;
c.1208G>A (S364N), 4.1%; c.1226A>G (N370S), 17.8%; c.1246G>A (G377S), 17.6%; c.1289C>T (P391L), 8.5%; c.1448T>C (L444P),
3%; and c.1504C>T (R463C), 24.5%. Recombinant alleles, deletion of 55 bp in exon 9 and 84GG mutation were considered as
mutations with no residual enzymatic activity.
Results: The ERA showed a statistically significant correlation with chitotriosidase (P<0.001), age (P<0.001), spleen size
(P<0.001), ‘Zimran’s Severity Score Index’ (P<0.01) and the ‘Gaucher Disease Severity Score Index—Type I’ (P< 0.0001) at
diagnosis of the disorder. Previous to any medical intervention, a comparison between the ERA and bone involvement, dem-
onstrated a statistically significant relationship (P<0.01) between the two variables.
Conclusions: This study data allowed us to define a new criterion for prognostic assessment of the disease at diagnosis,
called Protein Severity Index, which expresses the theoretical severity of the genotype presented by patients, according to
the corresponding ERA.
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Introduction
Gaucher disease (GD) type I (OMIM # 230800) is a lysosomal dis-
ease inherited with an autosomal recessive pattern, encom-
passing the signs and symptoms occurring in patients with a
congenital disorder in the glycolipid metabolism, leading to gly-
cosylceramide accumulation. This substance derives from the
cellular membrane of senescent leukocytes and it accumulates
in lysosomes of tissue macrophages, due to the deficiency in
the enzyme glycocerebrosidase or b-glycosidase (EC 3.2.1.45).1
The gene codifying b-glycosidase is the glucocerebrosidase
(GBA) gene, localized in chromosome 1 (q21–q31).2 Mutations in
GBA altering the stability of the enzyme or its active site are the
main cause of GD. Up to date, more than 300 different muta-
tions in GBA have been described and gathered in databases,
such as The Human Gene Mutation Database at the Institute of
Medical Genetics in Cardiff (http://www.hgmd.cf.ac.uk/ac/
index.php). Out of these mutations, more than 80% are single
nucleotide substitutions and the rest correspond to complex
mutant alleles. The four mutant alleles N370S (c.1226 A>G),
L444P (c.1448 T>C), 84GG (c.84dupG) and ISV2þ 1 (c.115þ 1G>A)
are the most prevalent worldwide.3 Traditionally, it has been
claimed that it is not possible to foresee the severity of GD based
only on the genotype; although, patients with a N370S allele are
protected against neuropathic development of the disease,
while homozygous patients for L444P probably do develop
neuropathic pathology.4
In 2001, we published the characterization of 10 defective al-
leles of GBA with high prevalence in the Spanish population.5
Fifteen years later, we plan to use the enzymatic residual activ-
ity (ERA) data obtained at the time—by means of expressing
each allele individually—to study the putative correlation be-
tween the genotype and phenotype in a series of patients with
predominately GD type I, in order to use this variable to guide
genetic advice.
Materials and methods
We conducted a non-interventionist study, in which six phys-
icians from five different University hospitals in Spain, located
in the cities of Badajoz, Madrid, Seville, Valencia and Zaragoza,
voluntarily participated and were submitted the clinical data.
Every participating physician provided the first data registered
in the clinical history of their patients with GD at the moment
of diagnosis. The data provided included age, gender, genotype,
hemoglobin and platelets values, liver and spleen size were
measured in cm below costal rib margin, presence or absence of
splenectomy, the activity of plasmatic chitotriosidase, and the
Zimran’s severity score index (SSI).6 Since every patient (except
one type III) had GD type I, the ‘Gaucher Disease SSI—Type I’
(GauSSI-I) was calculated.7 Special attention was placed on the
assessment of bone pathology, which was classified as follows:
(i) no bone pathology, (ii) mild bone pathology (osteopenia/
osteoporosis or bone pain with no other alteration) and (iii) se-
vere bone pathology (any bone lesion other than osteopenia/
osteoporosis or bone pain with no other alteration).
The residual enzyme activity in each patient was estimated
by adding the activity obtained after individually expressing
each of the two alleles responsible for the disease in COS-1
cells.5 The residual activities corresponding to the mutant al-
leles have been previously published and are shown in Table 1.
After excluding those patients with a genotype containing
an allele not previously expressed in COS-1 cells, the final num-
ber of patients was 45, and all of them had been diagnosed with
GD years earlier by a reduced activity of acid b-glycosidase in
leukocytes. Mutant recombinant alleles, the 55 bp deletion in
exon 9 and the 84GG mutation were considered as mutations
with no residual enzymatic activity.
Statistics
The statistical analyses were conducted using the SPSS 20.0 soft-
ware. Qualitative variables were expressed as percentages and
quantitative variables by measures of central tendency and dis-
persion (mean, standard deviation and range). A 95% confidence
interval was calculated for the means. The normality of the vari-
ables was assessed by the Kolmogorov–Smirnov test. The correl-
ation between quantitative variables was performed using the
Pearson correlation or Spearman rho, according to the normality
of the variable. Both, the Zimran’s SSI and the GauSSI-I were nor-
malized for the maximum score of both indexes in our popula-
tion (26 in the case of the Zimran’s SSI, and 17 in the case of the
GauSSI-I index) to perform correlation analyses with other vari-
ables. Significance was considered for correlations with P< 0.05.
A comparison between the ERA and bone pathology was per-
formed by means of the analysis of variance (ANOVA) test, and
later on the post hoc analysis to assess the correlation between
the ERA and bone pathology of any degree. Last, receiver operat-
ing characteristic (ROC) curves were performed to obtain the cor-
relation of bone pathology with the different quantitative
variables; when the correlation was significant, the optimal cut-
off diagnostic point of such variable was obtained.
Table 1. Residual activities corresponding to expressed wild type
and mutant alleles
Plasmid Activity (nM/h/mg) Corrected expression %
GBA wild type 69.0 233.5 100
T134P 2.4 2.4 1
G202R 28.1 39.9 17
G325W 24.2 32.5 14
S364N 9.4 9.6 4
N370S 35.6 41.6 18
G377S 31.4 40.8 18
P391L 6.9 19.7 9
L444P 6.9 6.9 3
R463C 28.6 57.2 24
Figure 1. Genotypes of the studied population and ERA.
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Results
Out of the 45 patients with GD, 51% were males. Mean age at
diagnosis was 23 years (range 1–68). The most frequent geno-
type was the N370S/L444P (28%), followed by N370S/N370S (21%)
and N370S/c.1263del55 (13%) (Figure 1). Clinical and biological
parameters are shown in Table 2. At the moment of diagnosis,
the mean residual activity was 21 (range 0–41). Thirty-nine
point five percent of patients had no bone disease; 30% had
mild disease and 30% severe disease (Figure 2).
When assessing the correlation of the residual enzymatic ac-
tivity with the chitotriosidase, age at diagnosis and spleen size, a
moderate correlation statistically significant (P< 0.001) was
observed, in a way such that the lower residual activity, the
greater were the chitotriosidase activity and the spleen size, and
the earlier the age at diagnosis. And this is exactly the same thing
happens with the Zimran´s SSI and the GAUSS-I score (P< 0.001).
No significant correlation was observed between the residual en-
zymatic activity and hemoglobin, platelets values or liver size.
The Zimran’s SSI and GauSSI-I were determined at diagnosis
with a mean of 7.9 (range 1–26) and 7.44 (range 1–17), respect-
ively. By means of the Spearman test, it was confirmed a great
correlation between both severity indexes (r ¼ 0.691, P< 0.0001).
Both indexes were normalized as stated in methods for the fol-
lowing correlation analyses. The correlation between the
Zimran’s SSI and the residual enzymatic activity was moderate
and statistically significant (r ¼ 0.548, P< 0.01) and that be-
tween the GauSSI-I index and the residual enzymatic activity
was strong (r ¼ 0.665, P< 0.0001), in such a way that a lesser re-
sidual activity involves a more severe phenotype presented by
patients at diagnosis. A subanalysis in non-pediatric patients
(age 14 years or older) showed a similar moderate correlation
between the Zimran´s SSI and the residual activity (r ¼ 0.478,
P< 0.01), and a stronger correlation between the GauSSI-I index
and the residual activity (r ¼ 0.787, P< 0.0001).
The ANOVA test showed a statistically significant (P< 0.01)
association between the residual enzymatic activity and bone
pathology (Levene statistic: 0.104, F: 9.152, P¼ 0.001). In the post
hoc analysis (Scheffe test), a statistically significant difference of
greater magnitude was observed in the correlation between the
residual activity and the group with bone disease, whether it
was mild or severe (Mild bone disease F:19.23, Severe bone dis-
ease F: 20.33, P< 0.05).
The correlation between bone disease and the different
quantitative variables was obtained by means of ROC curves and
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Figure 2. Patients percentage with different degree of bone disease.
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were significant: Zimran’s SSI (Area Under the Curve
(AUC):0.872; 95% CI¼ 0.766–0.979); GauSSI-I (AUC:0.799; 95%
CI¼ 0.666–0.931); Splenomegaly (AUC:0.721; 95% CI¼ 0.562–0.879)
and Hepatomegaly (AUC:0.695; 95% CI¼ 0.523–0.867).
Discussion
Our study demonstrates that the residual activity obtained from
these rare expressed mutant proteins justify a percentage of the
clinical profile observed in these Spanish patients, before any
intervention. However the clinical experience with GD and the
results of genotype/phenotype correlation studies suggest that
GBA deficiency is necessary but not sufficient to explain the ul-
timate clinical outcome.8 In general, the great variability in sys-
temic involvement in GD patients requires considering that
there are other underlying mechanisms playing a very import-
ant role such as promoter mutations, environment, and other
epigenetics and non-genetic causes.9
Despite the limitations of this study we consider it is import-
ant to communicate our findings to the Gaucher´s scientific com-
munity. In the 1990s, the expression studies performed by
Grabowski et al.10 and Grace et al.11 showed that the mutations
involving exons 5, 8, 9 and 10 are the ones causing the greatest
impact in the catalytic activity of the enzyme. Yet, there are
many mutations described in the literature which have not been
studied in vitro. Thus, it has not been possible to establish a com-
plete classification of the alleles able to determine the severity of
their phenotype according to their expression. In the studied pa-
tients sample, it is clear the statistical correlation between the
residual enzymatic activity—calculated as the addition of the ex-
pression percentage of both alleles with respect to the normal
protein expressed in mammalian cells—and determined biolo-
gical and clinical parameters before any intervention.
Particularly noticeable is the correlation at disease diagnosis,
such as age, activity of plasmatic chitotriosidase, spleen size and
Zimran´s SSI. Furthermore it is mainly illustrative the high correl-
ation between the residual enzymatic activity and the GauSSI-I
coefficient. The GauSSI-I index is the most valuable tool from a
clinical and phenotypical point of view and for the first time, its
correlation with the presence or absence of bone involvement
has been shown. In addition, the current study shows that, at
least in this series of patients the GauSSI-I and the Zimran´s SSI
show a high correlation; thus, a more severe genotype—that
with lower residual activity from the alleles responsible for the
disease—causes a more severe phenotype and vice-versa.
The main limitation of the study is the individual assessment
of the alleles; thus, we still need to find out what happens with the
residual activity when both alleles are expressed at the same time.
In view of the report data, we can define a new criterion for
prognostic evaluation at disease diagnosis, which we have
called Protein Severity Index, which expresses the theoretical
severity of the patient genotype, according to the corresponding
residual enzymatic activity. Further studies with a high number
of patients should be performed to establish the utility of this
new prognosis index.
Conclusions
The study shows that the mutations found in this group of pa-
tients cause a decrease of the enzymatic activity, constituting
the first link in the chain of events participating in the patho-
genesis of GD, and explaining a significant amount of the final
phenotype. In addition, this finding allows for the classification
of the studied mutations according to their severity, with the
corresponding implications from the point of view of genetic
advice and disease prognosis.
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